NCT04082416已完成3 期
A Phase III, Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-exploring Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 335
- 试验地点
- 1
- 主要终点
- SLE Responder Index (SRI) Response Rate
研究概览
简要总结
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active SLE disease#and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria
- •Age & Gender: Male or female between 18 and 65 years of age inclusive#and the sex ratio is not limited
- •Signed informed consent form#willing or able to participate in all required study evaluations and procedures.
- •SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .
- •Autoantibody-positive
- •on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate
排除标准
- •kidney disease ：Severe lupus nephritis 8 weeks prior to randomization (designed as:Urine protein>6g/24h or serum creatinine ( SCr>2.5mg/dL or 221umol/L ) or needing for hemodialysis or receipting high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)
- •Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular accident, encephalitis, central nervous system vasculitis;
- •there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;
- •Evaluation criteria for severity :
- •Alanine aminotransferase#ALT#or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN);
- •Creatinine Clearance (Ccr)<30ml/min;
- •White Blood Cell Count(WBCs)<2.5x 10(9)/L;
- •hemoglobin<85g/L;
- •Platelets<50x 10(9)/L.
- •Have a historically active hepatitis or active hepatitis or medical history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C: Patients with hepatitis C antibody positive are excluded;
- •Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;
- •Pregnant , lactating women and men or women who have birth plans in the past 12 months ;
- •Have a history of allergic reaction to human biological medicines.
- •Receipt of live vaccine within 1 month;
- •Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
- •Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.
- •Receipt of anti-tumor necrosis factor#interleukin receptor antagonist#
- •Receipt of IV immunoglobulin(IVIG),prednisone>100mg/d more than 14 days or plasma exchange;
- •There are active infections (such as herpes zoster, human immunodeficiency virus (HIV) virus infection, active tuberculosis, etc.) during the screening period;
- •Patients have depression or the significant suicide ideation;
- •Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese medicine preparation containing Tripterygium Wilfordii were used within 28 days before randomization
- •Investigator considers candidates not appropriating for the study.
结局指标
主要结局
SLE Responder Index (SRI) Response Rate
时间窗: Week 52
At Week 52 the percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment
次要结局
- The flare time after randomization(52 weeks)
- Mean Change From Baseline in Serological Examination Index(week 52)
- Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day，During Weeks 44 Through 52.(Week 44 through 52)
- Percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score(Week 52)
- Mean Change From Baseline in Physician's global assessment(PGA)(Week 52)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)Systemic Lupus ErythematosusNCT02885610RemeGen Co., Ltd.249
已完成
3 期
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.Moderate and Severe RheumatoId ArthritisNCT03016013RemeGen Co., Ltd.480
终止
3 期
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum DisordersNeuromyelitis Optica Spectrum DisordersNCT03330418RemeGen Co., Ltd.178
进行中（未招募）
3 期
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific AntibodyMalignant AscitesNCT06432296Wuhan YZY Biopharma Co., Ltd.312
已完成
2 期
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerPrimary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian CancerNCT06173037RemeGen Co., Ltd.43